Climb Bio hosts R&D Spotlight webcast on budoprutug CD19 program opportunity

Climb Bio

Climb Bio

CLYM

0.00
  • Climb Bio will host an R&D Spotlight webcast on budoprutug on May 5, 2026, at 8:00 a.m. ET.
  • Session will outline development strategy for budoprutug, anti-CD19 antibody in trials for primary membranous nephropathy, immune thrombocytopenia, systemic lupus erythematosus.
  • David Jayne, University of Cambridge, will join management as guest speaker.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Climb Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604080700PRIMZONEFULLFEED9685814) on April 08, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.